Sodium Valproate is the Most Likely Culprit for Lichenoid Dermatitis
Sodium valproate (valproic acid) is the most likely drug responsible for this patient's lichenoid dermatitis, as it is well-documented to cause psoriasiform and lichenoid drug eruptions in patients taking anticonvulsants. 1, 2
Evidence Supporting Valproate as the Causative Agent
Direct Evidence of Valproate-Induced Lichenoid/Psoriasiform Eruptions
Sodium valproate has been specifically reported to cause psoriasiform eruptions in multiple case reports and case series, with the causal relationship established through clinical presentation and positive immunologic testing (macrophage migration inhibition test and indirect rat mast cell degranulation test). 1
A documented pediatric case demonstrated psoriasiform drug eruption directly associated with sodium valproate use, emphasizing that early detection and drug elimination are essential for therapeutic success. 2
Physicians are advised to be aware that sodium valproate-induced psoriasiform eruptions may be more common than previously reported, and the drug should be added to the list of medications that produce psoriasiform and lichenoid reactions. 1
Why Other Medications Are Less Likely
Methylprednisolone (stopped 5 days ago): Systemic corticosteroids are actually used to treat lichenoid dermatitis and lichen planus, not cause them. 3 The recent discontinuation makes it an unlikely culprit, though abrupt steroid withdrawal can worsen underlying inflammatory conditions. 3
Brivaracetam: The FDA label lists common side effects as drowsiness, dizziness, fatigue, nausea, and psychiatric symptoms (aggression, anxiety, irritability), but does not mention lichenoid or psoriasiform eruptions as recognized adverse effects. 4
Bilastine (antihistamine): Antihistamines are commonly used to treat pruritus associated with lichenoid conditions, not cause them. 3, 5
Shelcal (calcium supplement): Calcium supplements have no documented association with lichenoid dermatitis.
Clinical Context: Mycosis Fungoides and Lichenoid Changes
Important Diagnostic Consideration
Mycosis fungoides itself can present with lichenoid histologic patterns, and this subset of patients tends to have intense pruritus and may have a poorer prognosis. 6 However, the temporal relationship with drug exposure and the patient's medication history strongly suggests a drug-induced etiology rather than disease progression.
Giant cell lichenoid dermatitis has been described in mycosis fungoides, though most cases of this unusual pattern are considered drug eruptions. 7 This further supports considering drug-induced lichenoid dermatitis in this patient.
Distinguishing drug-induced lichenoid eruption from lichenoid MF requires careful evaluation for lymphocyte atypia, prominent basal cell layer epidermotropism, and presence of plasma cells and eosinophils. 6
Recommended Management Approach
Immediate Action
Discontinue sodium valproate immediately after consulting with the prescribing neurologist to ensure safe transition to an alternative anticonvulsant that does not cross-react (avoid carbamazepine, which also causes psoriasiform eruptions). 1, 2
Initiate treatment with high-potency topical corticosteroids (clobetasol 0.05% or fluocinonide 0.05% cream/ointment) or tacrolimus 0.1% ointment for the lichenoid dermatitis. 3
Consider oral antihistamines for pruritus control and oral prednisone if the eruption is moderate to severe. 3
Monitoring and Follow-up
Expect improvement within 2-4 weeks after drug discontinuation, though complete resolution may take longer. 1, 2
If no improvement occurs after 4 weeks of appropriate treatment and drug discontinuation, consider skin biopsy to rule out progression of the underlying mycosis fungoides to a lichenoid variant. 6
Coordinate with neurology to select an alternative anticonvulsant; avoid carbamazepine as it also causes psoriasiform eruptions. 1
Common Pitfalls to Avoid
Do not assume the lichenoid dermatitis represents progression of mycosis fungoides without first considering and eliminating drug-induced causes, particularly in patients on known culprit medications. 1, 2
Do not continue the offending medication while attempting to treat the eruption with topical therapies alone—identification and elimination of the causative drug are essential for therapeutic success. 1, 2
Do not abruptly discontinue valproate without neurologic consultation, as sudden withdrawal can precipitate seizures or status epilepticus. 8